To tackle the global TB epidemic effectively, novel treatment strategies are critically needed
to shorten the duration of TB therapy and treat drug-resistant TB. Drug development for TB …

Application of clinical pharmacology best practices is essential to the efficient and rational
development of drugs. In general, knowledge gained about exposure–response …

The development of novel tuberculosis (TB) multi-drug regimens that are more efficacious
and of shorter duration requires a robust drug development pipeline. Advances in …

Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Introduction: Tuberculosis (TB) remains the leading cause of death from a curable infectious
disease; drug-resistant TB threatens to dismantle all prior gains in global control. Suboptimal …

Novel tuberculosis (TB) drug regimens are urgently needed, and their development will be
enabled by improved preclinical approaches that more effectively inform and ensure safe …

Tuberculosis now ranks as the leading cause of death in the world due to a single infectious
agent. Current standard of care treatment can achieve very high cure rates for drug-sensitive …

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

NEW TOOLS to improve the treatment and control of tuberculosis (TB) are a critical
component of any comprehensive strategy to eradicate the global TB epidemic. In particular …

Current tuberculosis (TB) treatment is based on a combination of drugs that were developed
mostly in the central decades of the last century. Cure rates are high for drug sensitive …